FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913790807> ?p ?o ?g. }

• W2913790807 endingPage "176.e1" @default.
• W2913790807 startingPage "169" @default.
• W2913790807 abstract "Long-term responders (LTRs) are defined by at least 18 months of response to sunitinib in metastatic clear-cell renal cell carcinoma (ccRCC). Well-described by clinical studies, the phenotype of these tumors has never been explored.In a retrospective and multicenter study, 90 ccRCCs of patients with metastatic disease were analyzed. Immunohistochemistry (carbonic anhydrase IX, vascular endothelial growth factor, c-MET, programmed death-ligand 1 [PD-L1], and PD-1) and VHL status were performed. Progression-free survival and overall survival were calculated from sunitinib introduction and from progression. LTRs and their corresponding tumors were compared with others using univariate and multivariate analysis.Twenty-eight patients were LTRs. They had a median progression-free survival of 28 months versus 4 months for other patients (P < .001). Similarly, LTRs had a median overall survival of 49 months versus 14 months (P < .001), even from progression (median, 21 vs. 7 months; P = .029). They were associated with a favorable or intermediate risk (International Metastatic Renal Cell Carcinoma Database Consortium model) (P = .007) and less liver metastasis (P = .036). They experienced more frequent complete or partial responses at the first radiologic evaluation (P = .035). The corresponding ccRCCs were associated with less nucleolar International Society for Urological Pathology grade 4 (P = .037) and hilar fat infiltration (P = .006). They were also associated with low PD-L1 expression (P = .02). Only the International Metastatic Renal Cell Carcinoma Database Consortium model and PD-L1 expression remained significant after multivariate analysis (P = .014 and P = .029, respectively).Primary tumor characteristics of LTRs were studied for the first time and demonstrated a different phenotype. Interestingly, they were characterized by low expression of PD-L1, suggesting a potentially lower impact of targeted immunotherapy in these patients." @default.
• W2913790807 created "2019-02-21" @default.
• W2913790807 creator A5004888910 @default.
• W2913790807 creator A5005586319 @default.
• W2913790807 creator A5006462902 @default.
• W2913790807 creator A5021549650 @default.
• W2913790807 creator A5028890871 @default.
• W2913790807 creator A5040427314 @default.
• W2913790807 creator A5040832651 @default.
• W2913790807 creator A5049425103 @default.
• W2913790807 creator A5052014340 @default.
• W2913790807 creator A5061266716 @default.
• W2913790807 creator A5061813933 @default.
• W2913790807 creator A5078599853 @default.
• W2913790807 creator A5081990675 @default.
• W2913790807 creator A5082534821 @default.
• W2913790807 creator A5086771566 @default.
• W2913790807 creator A5088487307 @default.
• W2913790807 creator A5088899598 @default.
• W2913790807 date "2019-06-01" @default.
• W2913790807 modified "2023-09-28" @default.
• W2913790807 title "Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression" @default.
• W2913790807 cites W1786251417 @default.
• W2913790807 cites W1962590198 @default.
• W2913790807 cites W1991408439 @default.
• W2913790807 cites W2010225305 @default.
• W2913790807 cites W2014138441 @default.
• W2913790807 cites W2017322644 @default.
• W2913790807 cites W2019607817 @default.
• W2913790807 cites W2068919366 @default.
• W2913790807 cites W2069701490 @default.
• W2913790807 cites W2070640824 @default.
• W2913790807 cites W2073860687 @default.
• W2913790807 cites W2097976367 @default.
• W2913790807 cites W2102575291 @default.
• W2913790807 cites W2108389924 @default.
• W2913790807 cites W2109666777 @default.
• W2913790807 cites W2113322173 @default.
• W2913790807 cites W2117924296 @default.
• W2913790807 cites W2119964871 @default.
• W2913790807 cites W2129407204 @default.
• W2913790807 cites W2140116071 @default.
• W2913790807 cites W2149456801 @default.
• W2913790807 cites W2154146769 @default.
• W2913790807 cites W2165625761 @default.
• W2913790807 cites W2201672580 @default.
• W2913790807 cites W2222086386 @default.
• W2913790807 cites W2618783355 @default.
• W2913790807 doi "https://doi.org/10.1016/j.clgc.2019.01.014" @default.
• W2913790807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30837208" @default.
• W2913790807 hasPublicationYear "2019" @default.
• W2913790807 type Work @default.
• W2913790807 sameAs 2913790807 @default.
• W2913790807 citedByCount "2" @default.
• W2913790807 countsByYear W29137908072021 @default.
• W2913790807 countsByYear W29137908072023 @default.
• W2913790807 crossrefType "journal-article" @default.
• W2913790807 hasAuthorship W2913790807A5004888910 @default.
• W2913790807 hasAuthorship W2913790807A5005586319 @default.
• W2913790807 hasAuthorship W2913790807A5006462902 @default.
• W2913790807 hasAuthorship W2913790807A5021549650 @default.
• W2913790807 hasAuthorship W2913790807A5028890871 @default.
• W2913790807 hasAuthorship W2913790807A5040427314 @default.
• W2913790807 hasAuthorship W2913790807A5040832651 @default.
• W2913790807 hasAuthorship W2913790807A5049425103 @default.
• W2913790807 hasAuthorship W2913790807A5052014340 @default.
• W2913790807 hasAuthorship W2913790807A5061266716 @default.
• W2913790807 hasAuthorship W2913790807A5061813933 @default.
• W2913790807 hasAuthorship W2913790807A5078599853 @default.
• W2913790807 hasAuthorship W2913790807A5081990675 @default.
• W2913790807 hasAuthorship W2913790807A5082534821 @default.
• W2913790807 hasAuthorship W2913790807A5086771566 @default.
• W2913790807 hasAuthorship W2913790807A5088487307 @default.
• W2913790807 hasAuthorship W2913790807A5088899598 @default.
• W2913790807 hasBestOaLocation W29137908071 @default.
• W2913790807 hasConcept C121608353 @default.
• W2913790807 hasConcept C126322002 @default.
• W2913790807 hasConcept C142724271 @default.
• W2913790807 hasConcept C143998085 @default.
• W2913790807 hasConcept C144301174 @default.
• W2913790807 hasConcept C204232928 @default.
• W2913790807 hasConcept C2777472916 @default.
• W2913790807 hasConcept C2777546739 @default.
• W2913790807 hasConcept C2778560582 @default.
• W2913790807 hasConcept C2779013556 @default.
• W2913790807 hasConcept C2779490328 @default.
• W2913790807 hasConcept C2781278892 @default.
• W2913790807 hasConcept C38180746 @default.
• W2913790807 hasConcept C71924100 @default.
• W2913790807 hasConcept C90924648 @default.
• W2913790807 hasConceptScore W2913790807C121608353 @default.
• W2913790807 hasConceptScore W2913790807C126322002 @default.
• W2913790807 hasConceptScore W2913790807C142724271 @default.
• W2913790807 hasConceptScore W2913790807C143998085 @default.
• W2913790807 hasConceptScore W2913790807C144301174 @default.
• W2913790807 hasConceptScore W2913790807C204232928 @default.
• W2913790807 hasConceptScore W2913790807C2777472916 @default.
• W2913790807 hasConceptScore W2913790807C2777546739 @default.

• next